We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+42.48%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$9.22M
Cap. Flow
-$20.8M
Cap. Flow %
-9.11%
Top 10 Hldgs %
62.39%
Holding
90
New
18
Increased
18
Reduced
19
Closed
27

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$13.7M
2
MRK icon
Merck
MRK
+$9.87M
3
DHR icon
Danaher
DHR
+$3.66M
4
SNY icon
Sanofi
SNY
+$2.9M
5
MDT icon
Medtronic
MDT
+$2.48M

Top Sells

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$23.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.94M
3
AERI
Aerie Pharmaceuticals
AERI
+$6.83M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.25M
5
NVRO
NEVRO CORP.
NVRO
+$3.78M

Sector Composition

Rank Sector Weight
1 Healthcare 78.99%
2 Miscellaneous 12.59%
3 Industrials 7.51%
4 Communication Services 0.5%
5 Real Estate 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQL
26
DELISTED
Arqule Inc
ARQL
$1.64M 0.72%
289,618
-84,702
-23% -$482K
IVC
27
DELISTED
Invacare Corporation
IVC
$1.58M 0.7%
108,902
+9,000
+9% +$149K
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.57M 0.69%
273,817
+166,317
+155% +$951K
ABMD
29
DELISTED
Abiomed Inc
ABMD
$1.54M 0.67%
3,419
-2,175
-39% -$857K
ASND icon
30
Ascendis Pharma A/S
ASND
$16.3B
$1.35M 0.59%
19,054
-11,000
-37% -$757K
BSTC
31
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.28M 0.56%
+21,900
New +$1.12M
MODN
32
DELISTED
MODEL N, INC.
MODN
$1.15M 0.5%
72,283
+49,822
+222% +$872K
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.51B
$1.14M 0.5%
148,959
– –
SPPI
34
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.01M 0.44%
+60,000
New +$1.3M
PBYI icon
35
Puma Biotechnology
PBYI
$468M
$994K 0.44%
21,671
-2,253
-9% -$109K
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$964K 0.42%
+79,750
New +$1.12M
PODD icon
37
Insulet
PODD
$10.1B
$929K 0.41%
+8,765
New +$821K
CTRE icon
38
CareTrust REIT
CTRE
$9.22B
$918K 0.4%
51,264
-50,000
-49% -$881K
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
$918K 0.4%
60,412
+12,000
+25% +$184K
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$799K 0.35%
72,096
-35,000
-33% -$435K
DRNA
41
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$779K 0.34%
51,074
-33,926
-40% -$494K
TCDA
42
DELISTED
Tricida, Inc. Common Stock
TCDA
$737K 0.32%
+24,122
New +$708K
KIDS icon
43
OrthoPediatrics
KIDS
$617M
$718K 0.32%
+19,600
New +$600K
SGMO
44
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$678K 0.3%
+40,000
New +$608K
SPPI
45
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$672K 0.29%
+40,000
New +$866K
XRAY icon
46
Dentsply Sirona
XRAY
$2.22B
$631K 0.28%
+16,680
New +$695K
ELV icon
47
Elevance Health
ELV
$85.5B
$630K 0.28%
2,300
-2,700
-54% -$701K
CNC icon
48
Centene
CNC
$32B
$623K 0.27%
8,600
-7,400
-46% -$514K
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
$594K 0.26%
18,029
– –
EPZM
50
DELISTED
Epizyme, Inc
EPZM
$503K 0.22%
47,449
– –
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Eversept Partners held 90 positions worth $228M, up 4.2% from $219M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners withdrew a net $20.8M in Q3 2018, closing 27 positions and reducing 19 holdings. Its most notable exit was Quality Care Properties, Inc., an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Merck worth $10.6M.

  • Eversept Partners's largest Q3 2018 buy was Merck: 154,894 shares worth $10.6M.
  • Eversept Partners added most to Zogenix, Inc. in Q3 2018, an estimated $13.7M increase.
  • Eversept Partners's biggest Q3 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $6.83M.
  • Eversept Partners fully exited Quality Care Properties, Inc. in Q3 2018, selling an estimated $23.1M.
  • Eversept Partners's ten largest holdings make up 62% of its $228M portfolio in Q3 2018.
  • Eversept Partners opened 18 new positions and closed 27 in Q3 2018.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $228M.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.